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Condom failure in South Africa
To the Editor: It was with great interest that we read the recent 
editorial by Dr Khumalo1 in which she expressed concern 
regarding potential condom failure in Africa. The issue of 
condom failure is certainly important and we were most 
alarmed by the lack of prevalence data on condom failure in 
South Africa. In her literature search Dr Khumalo did not find 
any research on the prevalence of condom failure in Africa 
aside from that in pregnant women. 
We have been conducting HIV/AIDS behavioural 
surveillance research at a large public health clinic that provides 
sexually transmitted infection (STI) services in Cape Town 
and have collected data that can help shed light on this urgent 
problem. In anonymous behavioural surveys collected from  
1 729 men and 470 women receiving STI services we have 
found that 41% of men and 37% of women have experienced 
condom failure, defined as a broken, torn, or slipped-off 
condom. In a subsample of 202 patients who reported condom 
failure, 12% had used oil-based condom lubricants that are 
known to degrade latex, such as hand creams, vaseline, or 
oils. In another separate subsample of 214 patients who had 
experienced condom failure, 7% reported having practised 
dry sex, although we do not know if the dry-sex practices 
were directly associated with condom failure. These rates of 
30 - 40% of persons experiencing condom failure are similar to 
those reported in the US studies cited by Dr Khumalo.2,3 Our 
behavioural surveillance data confirm that condom failure is 
prevalent in at least some high-risk populations in South Africa 
and may be of particular concern in the populations at highest 
risk. The causes of condom failure remain undocumented as 
we found only a minority of cases potentially attributable to 
improper use of lubricants or dry-sex practices. 
As stated by Dr Khumalo, there are interventions that 
reduce condom failure and there are now brief counselling 
interventions that increase condom uptake and proper use in 
STI patients tested in South Africa.4,5 We must also remember 
that condoms succeed in preventing pregnancy, STI and HIV 
infection far more often than they fail. We therefore applaud 
Dr Khumalo’s call for more research as well as evidence-based 
guidelines that include skill-building techniques for improving 
correct and consistent use of condoms.
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Overestimation of the South African 
HIV incidence using the BED IgG 
assay?
To the Editor: We thank Rehle et al. for their important study 
of HIV incidence in South Africa,1 which we read with great 
interest.  We agree with the authors that the incidence of HIV 
in South Africa is probably extremely high, particularly among 
young women, and believe that the study will help us focus 
HIV prevention efforts on appropriate subgroups.  We have 
serious concerns, however, about the applicability of the BED 
IgG assay to the South African HIV epidemic.  In light of recent 
evidence, we are concerned that Rehle et al. have overstated the 
true absolute incidence of HIV in South Africa.
As the name implies, the BED assay was developed using 
sequences from HIV subtypes B, D and E.2  To compensate for 
imperfect sensitivity and specificity, Rehle et al. use a correction 
factor based on McDougal et al.’s study of subtype B virus.3  
Given that the majority of HIV infections considered by Rehle 
et al. were (apparently) of subtype C,1 the applicability of the 
McDougal correction, and indeed of the BED assay itself, to 
these samples is problematic.  More questions arise in light 
of a recent report by Karita et al.4 that the BED assay does not 
perform well in subtype C virus infections; investigators found 
a specificity of 71% (95% confidence interval (CI) 54 - 84%),4 
substantially different from one estimate of specificity used in 
the McDougal correction3 (94% for infections more than 360 
days in the past).  In addition, Karita et al. found that using 
the BED assay with the McDougal correction resulted in 
overestimation of incidence in prospective Ugandan samples 
(subtype not available, but probably A and D5), reporting a 
corrected BED incidence of 6.4% and a true incidence of 1.3 - 
1.7%.4
We are therefore concerned that the incidence figures 
reported by Rehle et al. may be overestimates.  If indeed 
these figures are incorrect, this will make future comparisons 
with more accurate measures of incidence difficult and could 
lead to spurious conclusions with regard to the course of the 
epidemic.  Given these concerns and the current UNAIDS 
recommendation against using the BED assay for incidence 
estimation,6 it would be helpful if the authors clarified their 
findings with a quantitative sensitivity analysis of their 
estimates.  Until the BED assay has been further validated, we 
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believe that BED-derived estimates of HIV incidence must be 
interpreted with caution.
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Drs Rehle, Shisana, Parker and Puren reply: Westreich and 
colleagues express concerns about the applicability of the BED 
capture enzyme immunoassay to the South African epidemic 
with HIV subtype C as the predominant HIV clade. 
The BED assay uses a multi-subtype peptide designed 
to cover all major HIV subtypes, not just subtypes B, E and 
D as its name may imply. The three main variants of the 
immunodominant region of gp41 were used to synthesise the 
BED peptide (B Parekh, Centers for Disease Control (CDC) 
– personal communication). These consensus sequences are 
well preserved and the inclusion of those sequences from the 
three subtypes B, E and D was found to be sufficient to cover all 
major (group M) subtypes of HIV prevalent in different areas 
of the world.1 The BED peptide is equivalently reactive among 
these HIV subtypes as assessed by saturation binding and end-
point titres.
In May 2006, an incidence validation meeting was held 
at the CDC where new study results were presented from 
China, Cote d’Ivoire, South Africa, Thailand, Uganda, the 
USA and Zimbabwe to address the concerns expressed by the 
UNAIDS Reference Group in December 2005.2,3 Working groups 
developed guidelines with detailed adjustment procedures 
for the estimation of HIV-1 incidence in cross-sectional, 
population-based serosurveys.4 Two separate studies showed 
similar misclassification rates among subtype B and subtype C 
infections and proposed their own adjustment formulae5 (and 
Hargrove J, et al., ‘Improved HIV-1 incidence estimates using 
the BED Capture Enzyme Immunoassay’ – in review).
Values for the imputed variables for both adjustment factors 
were validated in 2 532 specimens from 1 192 people with 
known date of seroconversion in HIV-1 subtypes B and C. 
The key imputed value in these adjustments is the false recent 
rate among long-term (> 1 year) infected people. It is 5.57% 
in both adjustments (1-γ in McDougal’s adjustment is equal 
to ε in Hargrove’s adjustment). Therefore, the McDougal and 
Hargrove adjustments have only been validated for HIV-1 
subtypes B and C where the proportion of long-term infection 
misclassifying as recent infections were quantified. The 
performance of these adjustments in populations with HIV-1 
subtypes A, D and E is not yet known and is being validated.
The study of Karita et al.6 quoted by Westreich and colleagues 
questions the validity of the adjustments applied in our 
analysis. However, in view of the large samples from which the 
McDougal and Hargrove adjustments were derived, a major 
limitation of the analysis by Karita et al. was the small sample 
size used in the BED performance assessment in subtype C 
specimens – only 117 samples from 26 Zambian volunteers. 
Furthermore, based on previous analysis of HIV subtype C 
seroconverter samples (Ethiopia, Zimbabwe) done at the CDC 
we have applied a window period of 180 days in our incidence 
calculation. This is in contrast to the window period of 153 days 
used by Karita et al.
In order to examine the plausibility of our HIV incidence 
estimates we compared the adjusted BED estimates with 
estimates derived from mathematical modelling, using the 
ASSA2003 AIDS and Demographic model.7 BED HIV incidence 
in the population aged 2 years and older was 1.4%, compared 
with 1.3% estimated by the ASSA model. A BED HIV incidence 
rate of 2.4% was found among individuals aged 15 - 49 years. 
The modelled HIV incidence was 2.2% for this age group. 
We therefore conclude that the adjusted BED HIV incidence 
estimates appear to provide plausible national HIV incidence 
estimates for South Africa. 
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Notwithstanding these encouraging results we remain 
actively involved in further validation studies not limited to 
the BED-CEIA but will also explore the suitability of testing 
algorithms involving, for example, antibody avidity testing. 
There is emerging consensus that validated laboratory 
based tests are the method of choice to estimate national 
HIV incidence and assess the impact of national prevention 
programmes.
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African section of e-journal Rural and 
Remote Health
To the Editor: We read with interest the SAMJ article ‘Scope 
and geographical distribution of African medical journals active 
in 2005’ by Siegfried et al.,1 and would like to bring to your 
readers’ attention the recent launch of an African section of the 
e-journal Rural and Remote Health (RRH). This regional section 
has a particularly African flavour, owing to its own editorial 
board and peer-review panel, but is under the umbrella of the 
international journal.  
We hope that the African section will add to the initiatives 
described by Siegfried et al. and address some of the issues 
raised in their article. RRH is an international, peer-reviewed, 
open-access journal. It is Medline-listed. It aims to offer wider 
world exposure for quality African research in the area of rural 
and remote health care education, policy and practice. We 
believe the issues of rural and remote health are relevant to 
most of Africa.
Because RRH is an electronic journal it affords authors timely 
publication on an article-by-article basis. In addition, the 
electronic format means that RRH is not geographically bound, 
and therefore offers rural and remote authors and users an all-
of-Africa approach to publication. 
In a recent RRH editorial to coincide with the launch of the 
African section, we recognised the impact of inadequate access 
to information on the problems of health and health care in 
Africa.2 We also discussed the issue of inequity in access to the 
Internet, which has been highlighted for urgent attention by 
the Commission for Africa,3 and recent initiatives to improve 
the current situation of variable access.4,5 We offer the African 
section of RRH as a small contribution towards this. 
The Journal can be accessed at www.rrh.org.au. Users should 
select ‘African section’ from the main menu on the home page. 
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